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REFERENCE & DESIGN POPULATION INTERVENTION COMPARISON OUTCOME RISK OF BIAS
Gable  2005
Psychotropic medication use at a : A retrospective 
chart review and descriptive data analysis.
Anorexia Nervosa  N=31/60 Male (8)and 
Female (23)
Age range 12-46 years, mean 20.4
Inpatient (19) and outpatients (12)at 
private facility
Aripiprazole  dose not listed 14/60
12 months study, mean duration of 
treatment 35 days
Nil
Rated on discharge as  improved (achieved ideal body weight, 
stabilised mood, reduced eating disorder symptoms/achieved 
remission or reduced suicidal ideation), no change  or 
decompensated from admission. 35% of inpatients on an 
antipsychotic were rated as improved
Selection bias – high risk
Performance bias – high risk
Detection bias – high risk
Attia, Kaplan, Scroeder 2005
Open label randomised study
Anorexia Nervosa N=22
Adult outpatients
Aripiprazole
Olanzapine Nil available Attrition bias –high risk
Aragona 2007
Tolerability and efficacy of aripiprazole in a case of 
psychotic anorexia nervosa comorbid with epilepsy 
and chronic renal failure. Eating and weight 
disorders 12; 3; e54.
Case report.
Anorexia Nervosa N=1
34y Female Outpatient
Psychotic Disorder NOS. Epilepsy. Renal 
failure.
Raynaud Syndrome.
Aripiprazole 30mg daily  duration 6 
months
+ Carbamazepine +  Enalapril + Pipemidic
acid + Buflomedil + Sertraline + 
Risperidone
Weight change 51kg (BMI 18.3) to 52.7 kg
SANS and SAPS improved
At one year follow up HAM-D =15, HAM-A=9, Y-BOCS=6, BULIT-
R=81
At two year follow up HAM-D = 6, HAM-A=6, Y-BOCS=3, BULIT-
R=56
Selection bias- high risk
Publication bias – high risk
Trunko, Schwartz, Terry  2011
Aripiprazole in anorexia nervosa and low-weight 
bulimia nervosa: case reports. International journal 
of eating disorders 44; 3; 269-275
Case report
Anorexia Nervosa N=5
Age range 15-55y
Comorbid conditions: Depression NOS, 
OCD
Day Program, Intensive Outpatient 
program
Aripiprazole 5-10mg Duration 3mths to 
18mths
Other drugs: Citalopram, Duloxetine, 
Fluoxetine, Trazadone 
Nil
Increase in BMI of 2-4 points  (average 3) Selection bias – high risk
Performance bias – high risk
Marzola 2014
Atypical Antipsychotics as Augmentation Therapy in 
Anorexia Nervosa: Retrospective Chart Review 
Anorexia Nervosa total sample 75; 
N=23 Females on aripiprazole. Mean age 
26
Inpatients – Binge/Purge (10) ; Restrictive  
(13)
3 groups
SSRI alone / SSRI +olanzapine / 
SSRI + Aripiprazole 
Dose of Aripiprazole 9.13 +/- 6.33mg/day
Mean 4.96 +/- 1.62 weeks duration
Olanzapine + SSRI ; SSRI 
monotherapy
Aripiprazole group:
Mean BMI 14.11 to 15.21
Hamilton Rating scale for anxiety, 23.52  to 10; Depression 26.48  
to 12.17, Yale-Brown Cornell Eating Disorder Scale Total 18 .84 to
8.64 (large effect size)
Ari + SSRI was more effective than Ola + SSRI in treating purging 
episodes and better than both groups SSRI (p=0.09) and Ola +SSRI 
(p=0.57) for binges and reduction in YBC-EDS scores
Selection bias –low, 
Performance bias – high risk
Attrition bias- unclear
Launer 2015
Latest Developments in the Psychopharmacology 
of Anorexia Nervosa
Chart review, poster presentation
Anorexia Nervosa  
Insufficient data provided
N=? Age=? Female Inpatient
Comorbid OCD, Depression
Aripiprazole + venlafaxine
9 months duration
Nil Aripiprazole aided refeeding process. Unclear risk
Contreras 2015
Case report
Anorexia nervosa N=3
Female Adolescents
Comorbid Psychosis
Aripiprazole
6 months duration
Nil Improvement in psychosis and eating disorder symptoms
Selection bias- unclear risk
Reporting bias- unclear risk
Guido, Frank 2015
Aripiprazole, a partial dopamine agonist to 
improve adolescent anorexia nervosa—A case 
series 
DOI: 10.1002/eat.22485
Case series 
Anorexia Nervosa N=4
Female, Aged 12,12,12,17
Comorbid Separation and social anxiety 
disorder, GAD, MDD, PTSD
Inpatient and outpatient
Aripiprazole 1mg -5mg daily 
Duration -4 weeks to 12 months Average 
28.5
Fluoxetine 10mg, Ativan, Zoloft 50mg
Nil
Weight gain: percentage change in IBW
From 8 points to 13 points , average 10.75 
Reduced body image distortion N=3
increased social functioning N=1
increased insight N=1
Selection bias – high risk
Publication bias – high risk
STUDY SELECTIONBACKGROUND
• Changes in brain dopaminergic function have been implicated in the pathophysiology of anorexia 
nervosa from both preclinical and clinical studies (Kontis 2012:496-515, Brewerton 2012:398 405)
• Therapeutically, olanzapine has been a focus of clinical research with mixed efficacy findings 
(Kishi 2012:e757 e66, Brewerton 2012:398 405, Dold Psychotherapy and Psychosomatics 2015)
• Aripiprazole, as a D2 receptor partial agonist, may have additional benefit via dopaminergic 
modulation and be more favourable in this patient population due to less associated weight gain
AIMS
• To undertake a systematic review of the available literature of the efficacy of aripiprazole in the 
treatment of anorexia nervosa, in all age groups, clinical settings, languages and genders.
METHOD
• CINAHL, EMBASE, MEDLINE, PsycINFO and the Cochrane database were searched  using the 
search terms Anorexia nervosa, eating disorders, antipsychotics, aripiprazole (and its generics).
• Randomised controlled studies were sought primarily but all study types were included. Enquiries 
were made with pharmaceutical companies, experts in the field and other relevant researchers. 
RESULTS
• The only studies available were retrospective chart reviews and case reports/series.
• No published studies met the primary inclusion criteria of randomised placebo controlled trials.
• Results from one proposed randomised study were unavailable and authors did not respond to
requests for information/had no further data to add.
• Eight primary reports were found where aripiprazole was used to treat symptoms of anorexia
nervosa.
• Aripiprazole showed a positive effect on various eating disorder symptoms including weight gain, 
binge eating, purging and body image distortion. 
• In addition, aripiprazole was observed to aid the refeeding process, increase social functioning, 
increase insight  and was found to be acceptable to the patient group.
CONCLUSIONS
• Whilst positive outcomes for the use of aripiprazole in anorexia nervosa were identified, clear 
conclusions or recommendations cannot be made due to the inherent reporting bias, small sample 
sizes and lack of randomisation  or blinding in the studies reported. 
• Randomised studies are indicated to explore this further.
Records identified 
through on line 
databases (n=107)
Additional records 
identified through 
other sources (n=151)
Records after 
duplicates removed 
(n=107)
Studies included in 
quantitative synthesis 
(meta-analysis)  (n=0)
Studies of anorexia 
nervosa and 
aripiprazole (n=8)
Full text articles 
excluded with reasons 
(n=43)
Full text articles 
assessed for eligibility 
(n=51)
Records excluded
(n=56)
Records screened
(n=107)
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